Letromina

Letrozole 2.5mg

What is Letromina (Letrozole) 2.5mg?

Letromina is a pharmaceutical product containing Letrozole as its active ingredient, with each tablet providing a concentration of 2.5mg. Letrozole is categorized as an aromatase inhibitor and is specifically formulated for the comprehensive treatment of breast cancer in postmenopausal women. This medication is strategically employed in scenarios where patients have completed 5 years of adjuvant tamoxifen therapy or as an initial treatment for locally advanced or metastatic breast cancer with hormone receptor-positive or hormone receptor unknown status.

Indications:

Letromina tablets are meticulously designed to address specific conditions associated with breast cancer in postmenopausal women. The key indications for Letromina include:

1. Breast Cancer Treatment: Letromina is primarily indicated for the treatment of breast cancer, focusing on postmenopausal women. Postmenopause is characterized by the cessation of menstrual cycles, leading to changes in hormonal levels that can influence the development and progression of certain types of breast cancer.

2. Adjuvant Tamoxifen Therapy Completion: Letromina is recommended for postmenopausal women who have successfully completed 5 years of adjuvant tamoxifen therapy. Adjuvant therapy involves additional treatment provided after the primary treatment (e.g., surgery) to reduce the risk of cancer recurrence.

3. Initial Treatment for Locally Advanced or Metastatic Breast Cancer: Letromina serves as an initial treatment option for locally advanced or metastatic breast cancer. This includes cases where the cancer has spread beyond its original site or involves distant organs. Letromina is particularly effective when the breast cancer is hormone receptor-positive or when the receptor status is unknown.

How Does it Work?

Letrozole, the active ingredient in Letromina, acts as an aromatase inhibitor. Aromatase is an enzyme responsible for converting androgens into estrogen. By inhibiting aromatase, Letrozole reduces the production of estrogen, a hormone that can stimulate the growth of hormone receptor-positive breast cancer cells. Lowering estrogen levels is a crucial therapeutic approach to impede the progression of breast cancer in postmenopausal women.

Dosage and Administration:

Healthcare professionals determine the appropriate dosage and administration schedule for Letromina based on individual patient characteristics, the specific breast cancer condition, and the overall treatment plan. Letromina is typically administered orally, with or without food, as directed by the healthcare provider.

Onset of Action:

The onset of action of Letromina may vary among individuals. Patients are advised to adhere to the prescribed treatment schedule to maximize the therapeutic benefits.

Duration of Treatment:

The duration of Letromina treatment is determined by the healthcare provider based on individual response to therapy, overall treatment goals, and ongoing assessment of the patient's condition.

Monitoring and Follow-Up:

Regular medical monitoring and follow-up appointments are essential during Letromina treatment. Healthcare providers assess treatment efficacy, monitor potential side effects, and make any necessary adjustments to the treatment plan.

Presentation

Each carton contains 30 tablets of 2.5mg each.